CMS proposes faster prior-authorization rules for drugs
CMS has proposed new electronic prior-authorization rules for drugs that could shorten some approval waits, but the change is not final. The plan would still need public comments, a final rule, and plan-by-plan implementation before patients see any effect.
People waiting on a prescription approval may eventually see faster decisions under a new Centers for Medicare & Medicaid Services proposal — but nothing changes yet.
The April 10 proposal would expand electronic prior authorization for drugs, tighten some decision timeframes, and add more reporting on how plans handle requests and denials. CMS says the goal is to make the process more predictable for patients and less paperwork-heavy for clinicians.
What CMS is proposing
Prior authorization is the extra step some health plans require before covering certain drugs. In the proposed rule, CMS says impacted payers would have to support electronic prior authorization for more drug claims, use updated health IT standards, and share more information about their API systems and performance.
The agency is also proposing shorter turnaround times for some drug-related decisions. In the CMS fact sheet, those timeframes vary by plan type. For example, some Medicaid, CHIP, and marketplace plans would need to respond within 24 hours for certain requests or within 72 hours for standard marketplace requests, while expedited requests would be due within 24 hours. That means the details would not be identical for every plan.
Who could be covered
CMS says the proposal would affect Medicare Advantage organizations, Medicaid fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, Qualified Health Plan issuers on the federal exchanges, and, in a new expansion, small group market QHP issuers on the federally facilitated SHOP. The proposal would also apply differently depending on whether a drug is covered under a medical benefit or a pharmacy benefit.
That matters because a patient’s experience could still depend on the exact plan, benefit type, and whether the rule is finalized as written.
What this could mean for patients
If finalized and implemented, the rule could reduce some delays when a medication needs plan approval. CMS says electronic workflows could improve data exchange, speed documentation, and reduce repeat back-and-forth between prescribers and plans.
But faster technology does not guarantee an approval. Prior authorization can still be denied, and patients may still need appeals or more documentation. A 2023 systematic review in the Journal of Managed Care & Specialty Pharmacy found that prior authorization caused treatment delays, even though its effect on specialty drug use varied. CMS also points to the broader administrative burden that the proposal is meant to address.
What still has to happen
This is a proposal, not a final rule. CMS has asked for public comment, and the requirements could change before they are finalized.
Under the proposal, compliance would not start right away even after a final rule. CMS says some HIPAA-covered entities would have up to 24 months after the final rule’s effective date to comply, while small health plans would have 36 months. Other payer reporting requirements would begin sooner, including some deadlines tied to the effective date of the final rule.
CMS had already finalized an earlier interoperability and prior authorization rule in 2024, but that rule focused on non-drug items and services. The new proposal builds on that framework and extends parts of it to drugs.
What readers can do
If a prescription is delayed, ask the prescriber’s office or pharmacy whether prior authorization is the reason, and whether additional records or an appeal are needed. If your plan sends notices about coverage rules or prior authorization, read them carefully — the exact process can vary by insurer and benefit.
If a medication delay seems to be affecting urgent symptoms, contact the prescribing clinician promptly. For severe or rapidly worsening symptoms, seek urgent or emergency care.
For now, the main takeaway is simple: CMS is trying to speed up drug prior authorization, but patients are unlikely to feel the effects until the rule is finalized and plans update their systems.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
